This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Electromed, Inc. (ELMD) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bears are Losing Control Over Electromed, Inc. (ELMD), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Electromed, Inc. (ELMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Electromed, Inc. (ELMD) Lags Q1 Earnings Estimates
by Zacks Equity Research
Electromed, Inc. (ELMD) delivered earnings and revenue surprises of -16.67% and 11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Electromed, Inc. (ELMD) Reports Next Week: What Awaits?
by Zacks Equity Research
Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Electromed, Inc. (ELMD) Q4 Earnings Meet Estimates
by Zacks Equity Research
Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 0.00% and 1.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Electromed, Inc. (ELMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Electromed, Inc. (ELMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in the Surgical segment and new launches under Vision Care segment are likely to have driven growth in the second quarter for Alcon (ALC).
New Strong Sell Stocks for June 3rd
by Zacks Equity Research
ADSK, BNR, NET, ELMD, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on June 3, 2021
New Strong Sell Stocks for May 13th
by Zacks Equity Research
PRTS, CIGI, ELMD, LLY, and TTWO have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2021
Earnings Preview: Electromed, Inc. (ELMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Varian Medical (VAR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.
Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 225.00% and 15.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Electromed, Inc. (ELMD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Electromed Enters Oversold Territory
by Zacks Equity Research
Electromed has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Electromed Enters Oversold Territory
by Zacks Equity Research
Electromed has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS
4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus
by Debanjana Dey
Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
Zacks.com featured highlights include: Vista Outdoor, 21Vianet, Electromed and GAIN Capital
by Zacks Equity Research
Zacks.com featured highlights include: Vista Outdoor, 21Vianet, Electromed and GAIN Capital
4 Breakout Stocks for Explosive Returns
by Nitish Marwah
In order to select the right breakout stock one has to first calculate its support and resistance level.
5 Themes (& Picks) for Coronavirus Investing
by Sejuti Banerjea
Coronavirus is going to be around for a while, so let's use it to define our investment strategies.
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
by Zacks Equity Research
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
5 Stocks With Recent Price Strength Amid Coronavirus Logjam
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now
by Benjamin Rains
DexCom shares have soared 45% since March 18. The connected glucose monitoring systems firm is also expected to continue to grow and DXCM stock might be somewhat immune to the current coronavirus economic uncertainty...
5 Top Low-Beta Stocks Surged in March Defying Coronavirus
by Nalak Das
The global financial markets are currently witnessing one of the worst periods since the Great Depression due to the coronavirus-led crisis.